Cyclosporine in the treatment of psoriasis

Cutis

Volumn 66, Issue 5, 2000, Pages 365-369

  Gulliver, Wayne P ^a,b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Newlab Clinical Research Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN; DERMATOLOGICAL AGENT;

ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG INTERACTION; FOLLOW UP; HUMAN; KIDNEY; PATIENT SELECTION; PSORIASIS; RISK FACTOR; SKIN TUMOR; TIME;

CLINICAL TRIALS; CREATININE; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG INTERACTIONS; FOLLOW-UP STUDIES; HUMANS; KIDNEY; PATIENT SELECTION; PSORIASIS; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS;

EID: 0034328095     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol. 1998;139:88-95.
2. Shupack J, Abel E, Bauer E, et al. Cyclosporin as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol. 1997;36:423-432.
3. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral): a multicentre study. Br J Dermatol. 1997;136:527-530.
4. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-284.
5. Ho VC et al. Neoral® in the treatment of psoriasis: consensus treatment guidelines. J Cutan Med Surg. 1997;1:209-215.
6. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39:464-475.
7. Berth-Jones J, Voorhees JJ. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol. 1996;135:775-777.
8. Gulliver WP, Murphy GF, Hannaford VA, et al. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin. Br J Dermatol. 1996;135(suppl 48):35-39.
9. Elder C, Moore M, Chang CT, et al. Efficacy and pharmacokinetics of two formulations of cyclosporin A in patients with psoriasis. J Clin Pharmacol. 1995;35:865-875.
10. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. Br J Dermatol. 1999;141:283-291.
11. Kokelj F, Plozzer C, Torsello P, et al. Efficacy of Cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports). J Eur Acad Dermatol Venereol. 1998;11:177-179.
12. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis: the Methotrexate-Cyclosporine Combination Study Group. New Engl J Med. 1995;333:137-141.
13. Clark C, Kirby B, Morris A, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999;141:279-282.
14. Touraine JL, Traeger J, Betuel H, et al, eds. Cancer in Transplantation, Prevention and Treatment: Proceedings of the 27th Conference on Transplantation and Clinical Immunology. Vol. 27. The Netherlands: Kluwer Academic Publishers; 1996.